 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12...891011121314151617181920 |
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 16, 2016
P1, N=22, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 3: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 26, 2016
P3, N=1860, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2018 --> Mar 2018
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 26, 2016
P3, N=3176, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER 3: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 17, 2016
P3, N=1860, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2018 --> Mar 2018 Not yet recruiting --> Recruiting
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER 3: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Nov 18, 2015
P3, N=1860, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Apr 9, 2015
P1, N=54, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Mar 19, 2015
P1, N=32, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Mar 2, 2015
P1, N=54, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment (clinicaltrials.gov) - Feb 5, 2015
P1, N=56, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment (clinicaltrials.gov) - Jan 6, 2015
P1, N=60, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Dec 17, 2014
P2, N=632, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - Dec 5, 2014
P1, N=48, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Nov 13, 2014
P1, N=32, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function (clinicaltrials.gov) - Nov 7, 2014
P1, N=69, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment (clinicaltrials.gov) - Nov 5, 2014
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Feb 2015
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Oct 22, 2014
P1, N=78, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Oct 2014 --> Feb 2015 Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function (clinicaltrials.gov) - Oct 11, 2014
P1, N=72, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Sep 30, 2014
P1, N=54, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Sep 28, 2014
P1, N=32, Recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Sep 28, 2014
P1, N=54, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects (clinicaltrials.gov) - Sep 28, 2014
P1, N=32, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Sep 28, 2014
P1, N=78, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects (clinicaltrials.gov) - Aug 26, 2014
P1, N=52, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - Aug 5, 2014
P1, N=48, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Jun 26, 2014
P1, N=78, Recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (clinicaltrials.gov) - Jun 26, 2014
P1, N=78, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - Jun 13, 2014
P1, N=48, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects (clinicaltrials.gov) - Jun 12, 2014
P1, N=48, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects (clinicaltrials.gov) - May 5, 2014
P1, N=52, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects (clinicaltrials.gov) - Apr 24, 2014
P1, N=170, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 23, 2014
P2, N=603, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects (clinicaltrials.gov) - Feb 27, 2014
P1, N=52, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects (clinicaltrials.gov) - Feb 23, 2014
P1, N=52, Recruiting, Sponsor: Novo Nordisk A/S
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function (clinicaltrials.gov) - Jan 6, 2014
P1, N=72, Recruiting, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment (clinicaltrials.gov) - Dec 18, 2013
P1, N=60, Recruiting, Sponsor: Novo Nordisk
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function (clinicaltrials.gov) - Dec 16, 2013
P1, N=72, Recruiting, Sponsor: Novo Nordisk
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P2 trial: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Aug 13, 2013
P2, N=603, Active, not recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects (clinicaltrials.gov) - May 29, 2013
P1, N=170, Completed, Sponsor: Novo Nordisk A/S
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 14, 2013
P1, N=107, Completed, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects (clinicaltrials.gov) - Sep 25, 2012
P1, N=26, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 16, 2012
P1, N=107, Completed, Sponsor: Novo Nordisk
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects (clinicaltrials.gov) - Sep 10, 2012
P1, N=161, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects (clinicaltrials.gov) - Jun 12, 2012
P1, N=26, Completed, Sponsor: Novo Nordisk
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects (clinicaltrials.gov) - Apr 4, 2012
P1, N=161, Completed, Sponsor: Novo Nordisk